IBUDILAST ( DrugBank: Ibudilast )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	4
13	多発性硬化症／視神経脊髄炎	1

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04057898 (ClinicalTrials.gov)	May 28, 2020	6/8/2019	Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS	A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: MN-166;Drug: placebo	MediciNova	NULL	Recruiting	18 Years	80 Years	All	230	Phase 2/Phase 3	United States;Canada
2	EUCTR2019-003549-14-HU (EUCTR)	11/03/2020	13/01/2020	A Clinical Trial To Evaluate The Efficacy And Safety Of Mn-166 (Ibudilast) In Subjects With Amyotrophic Lateral Sclerosis(Lou Gehrig's disease)	A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS - COMBAT-ALS	Amyotrophic Lateral Sclerosis MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Ibudilast Product Code: MN-166 INN or Proposed INN: IBUDILAST	MediciNova, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	230	Phase 2;Phase 3	United States;Hungary;Greece;Poland;Spain;Germany;Italy
3	NCT02714036 (ClinicalTrials.gov)	May 6, 2016	9/3/2016	A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)	A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)	Amyotrophic Lateral Sclerosis	Drug: ibudilast	MediciNova	Massachusetts General Hospital;South Shore Neurologic Associates	Completed	18 Years	N/A	All	35	Phase 1/Phase 2	United States
4	NCT02238626 (ClinicalTrials.gov)	September 2014	4/9/2014	Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)	A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS)	Amyotrophic Lateral Sclerosis	Drug: Placebo (for MN-166);Drug: MN-166;Drug: riluzole	MediciNova	Atrium Health	Completed	18 Years	80 Years	All	71	Phase 2	United States

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01982942 (ClinicalTrials.gov)	November 2013	29/10/2013	Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis	A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis	Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Secondary Progressive	Drug: ibudilast;Drug: Placebo oral capsule	MediciNova	National Institutes of Health (NIH);National Institute of Neurological Disorders and Stroke (NINDS);National Multiple Sclerosis Society	Completed	21 Years	65 Years	All	255	Phase 2	United States